Chiesi Farmaceutici

• A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary Fibrosis

  Phase 1, Not yet recruiting, 18 people

• NCT07744386

  Phase 1, Not yet recruiting, 24 people, 4 Aug 2026

• A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  Phase 2, Recruiting, 240 people, 8 Apr 2026

• NCT06892756

  Phase 1, Completed, 30 people, 25 Mar 2025

• NCT05001074

  Collaborator, Phase 3, Status unknown, 145 people, 11 Aug 2021

• NCT04104646

  Phase 2, Terminated, 7 people, 26 Sept 2019

• NCT02970630

  Phase 2, Completed, 28 people, 22 Nov 2016

• NCT02904772

  Collaborator, Phase 2, Withdrawn, 0 people, 19 Sept 2016

• NCT02500212

  Phase 4, Completed, 75 people, 16 Jul 2015

• NCT02432833

  Phase 4, Completed, 428 people, 4 May 2015

Sources: clinicaltrials.gov

• IFN-Mediated Bronchial Epithelium Cellular Senescence in Chronic Obstructive Pulmonary Disease

  1 Dec 2025

Sources: api.crossref.org

• Developmental brain programmes and biomarker activation in Alzheimer's disease

  Employment, 3 Sept 2026

• Definitions, diagnostic criteria and assessment methods used in the diagnosis of sarcopenia: A scoping review

  Consulting or advice, Fees or honoraria, 21 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov

• SUN-645 Leptin- And Incretin-based Combination Therapy In Lipodystrophy: A Promising Metabolic Strategy?

  ENDO 2025 abstract, 23 Oct 2025